

1 **Supplementary information**

2 ***Supplementary Methods***

3 **Model overview**

4 The hepatic insulin signaling model included five signaling molecules, insulin receptor
5 (R), IRS1 (S_1), IRS2 (S_2), Akt (B), and aPKC (C). The model was fitted to two published
6 data sets simultaneously (described in the main text). The pre-hepatic insulin level has
7 not been measured in both data sets. The estimation of pre-hepatic insulin, namely the
8 input to the model, is also described below. All the simulation work was done based on
9 SBPD toolbox for Matlab ¹. The bifurcation analysis was done with Matcont ². Matlab
10 code for generating main figures in the main text and main Supplementary Figures are
11 included in Supplementary Software 1.

12

13 Given the fact that the number of unknown parameters is more than that of experimental
14 data points, we took a parsimonious manner in designing the model in order to have
15 minimal number of unknown parameters. Firstly, for those processes that no data is
16 available, multiple intermediary processes were lumped into one kinetic term. This
17 applied to insulin receptor and IRS1/2 activation. Secondly, for feedbacks that have
18 overlapping effects, we implemented only one that is upstream to others. This applied to
19 Akt, since Akt has been reported to positively feedback to insulin receptor ³, IRS1 ⁴ and
20 itself ⁵. In this case, only the feedback from Akt to insulin receptor was implemented in
21 the model (Akt auto-feedback was also tested). Lastly, interactions, including feedback
22 and crosstalk mechanisms, are represented in the model by Hill functions of the following
23 forms:

$$H_a(p, x) = p + (1 - p) \frac{x^2}{1 + x^2}$$

24 $H_i(p, x) = 1 - (1 - p) \frac{x^2}{1 + x^2}$




$$x = \frac{X}{m}$$

25 where the subscripts a and i indicate activation and inhibition, respectively. p is in the
26 range $[0, 1]$. X represents the concentration of the molecule that carries out the action, m
27 is the half-maximal concentration.

28 **Model**

29 **Insulin receptor (R)**

30 The insulin receptor is activated following insulin (I) binding. With physiological levels
31 of insulin ($<5\text{nM}$), binding of a second insulin molecule on the receptor is rare and
32 therefore is neglected here. The ligand binding and the following auto-phosphorylation of
33 the receptor are lumped into one kinetic term (r_{1f}). Dephosphorylation of activated
34 receptor (r_{1b}) is regulated by Akt (B_a) mediated feedback. The activated receptor (R_p)
35 then undergoes internalization (r_{2f}), which is regulated by aPKC (C_a). Internalized
36 receptor undergoes dephosphorylation (r_{3f}), which is also regulated by Akt (B_a), and
37 further reinsertion (r_{4f}). At physiological levels of insulin, most of the internalized
38 receptors recycle to the plasma membrane ⁶. Therefore, the degradation of internalized
39 receptors was not considered. The kinetic terms and the equations concerning insulin
40 receptors are:



41

$$\frac{dR}{dt} = -r_1 + r_4$$

$$\frac{dR_p}{dt} = -r_2 + r_1$$

$$\frac{dR_{p,en}}{dt} = -r_3 + r_2$$

$$\frac{dR_{en}}{dt} = -r_4 + r_3$$

42 **IRS1 (S_1)**

43 There is evidence that the total amount of IRS1 protein is not changed by postprandial
 44 insulin stimulation ⁷. This allowed us to model only activation and deactivation processes
 45 of IRS1, and to use the fraction of activated IRS1 (S_{1a}) as a variable in the model.

46

47 IRS1 is activated (b_{of}) and deactivated (b_{ob}) via tyrosine phosphorylation and
 48 dephosphorylation by the insulin receptor and phosphatases, respectively. The activity of
 49 IRS1 is also influenced by multiple downstream effectors in the insulin signaling network,
 50 such as Akt (B_a) and aPKC (C_a), which can phosphorylate multiple serine/threonine
 51 residuals on IRS1 ⁸. Importantly, serine/threonine phosphorylation on IRS1 can either
 52 improve or impair signaling. As the positive feedback from Akt on the receptor has
 53 already been implemented, only negative effect from Akt is included here. For aPKC, we
 54 set up two parallel models where the effect of aPKC on IRS1 is positive and negative,

55 respectively. Numerical studies showed that only a negative effect from aPKC on IRS1
 56 could fit the data sets. The kinetic terms and equations for IRS1 read:

$$57 \quad S_1 \rightleftharpoons S_{1a} \quad r_{b0} = b_{0f} (R_p + R_{p,en}) H_i(b_{0,p1}, \frac{C_a}{b_{0,m1}}) H_i(b_{0,p2}, \frac{B_a}{b_{0,m2}}) (1 - S_{1a}) - b_{0b} S_{1a}$$

$$\frac{dS_{1a}}{dt} = r_{b0}$$

58 **IRS2 (S_2)**

59 Unlike IRS1, the total amount of IRS2 protein showed remarkable decrease after feeding
 60 due to transcriptional inhibition by Akt-FoxO ⁷. Consequently, the synthesis (c_{0f}) of IRS2,
 61 which is regulated by Akt (B_a), is included in the model. The activation of IRS2 (c_{1f}) is
 62 modeled by one kinetic term. Activated IRS2 (S_{2a}) undergoes degradation (c_{2f}). The
 63 kinetic terms and equations for IRS2 read

$$null \rightarrow S_2 \quad r_{c0} = c_{0f} H_i(c_{0p}, \frac{B_a}{c_{0m}})$$

$$S_2 \rightarrow S_{2a} \quad r_{c1} = c_{1f} (R_p + R_{p,en}) S_2$$

$$64 \quad S_{2a} \rightarrow null \quad r_{c2} = c_{2f} S_{2a}$$

$$\frac{dS_2}{dt} = r_{c0} - r_{c1}$$

$$\frac{dS_{2a}}{dt} = r_{c1} - r_{c2}$$

65 **aPKC (C)**

66 There is evidence that the amount of aPKC in rodent liver is unchanged after feeding
 67 (Farese R. V. private communication). Therefore only the (de-)activation processes (d_{0f}
 68 and d_{2f}) are modeled and the fraction of activated aPKC (C_a) is used as a variable. aPKC
 69 is activated only by the IRS2 branch ⁹. The activation process requires IRS2/P13K

70 binding, (auto-)trans-phosphorylation and a conformational change (d_{1f})^{10,11}. The state
 71 before the conformational change is denoted by C_t . The kinetic terms and equations for
 72 aPKC read:

$$\begin{aligned}
 C &\rightleftharpoons C_t & r_{d0} &= d_{of} H_a(d_{0,p}, \frac{C_a}{d_{0,m}}) S_{2,a} (1 - C_t - C_a) - d_{ob} C_t \\
 C_t &\rightarrow C_a & r_{d1} &= d_{1f} C_t \\
 C_a &\rightarrow C & r_{d2} &= d_{2f} C_a \\
 \frac{dC_t}{dt} &= r_{d0} - r_{d1} \\
 \frac{dC_a}{dt} &= r_{d1} - r_{d2}
 \end{aligned}$$

74

75 Akt (B)

76 Akt is activated by both the IRS1 and IRS2 branches and is inhibited by aPKC. There is
 77 evidence that the total amount of Akt is kept constant during postprandial insulin
 78 stimulation⁷. As in the case of IRS1, the activated fraction of Akt (B_a) is used as variable
 79 and only the activation (e_{of}) and deactivation (e_{ob}) terms are present in the Akt equation.
 80 The kinetic terms and the equations for Akt read:

$$\begin{aligned}
 B &\rightleftharpoons B_a & r_{e0} &= e_{of} H_i(e_{0,p0}, \frac{C_a}{e_{0,m0}}) H_{a,a}(e_{0,p1}, \frac{S_{1,a}}{e_{0,m1}}, \frac{S_{2,a}}{e_{0,m2}}) (1 - B_a) - e_{ob} B_a \\
 \frac{dB_a}{dt} &= r_{e0}
 \end{aligned}$$

82 Estimation of rodent postprandial pre-hepatic insulin level

83 Information on rodent pre-hepatic vein insulin levels is rare. We found two publications
 84 in which both plasma and pre-hepatic insulin level have been measured simultaneously
 85^{12,13}. The data are summarized in the following Table.

site condition	plasma (pM)	pre-hepatic base/peak (pM)	fraction of pulsatile insulin
12 hour fast	256	200/630	60%
0.5 hour after hyperglycemic clamp	800	900/4500	60%

86

87 We assumed parabola relationships between plasma insulin level and the peak/base level
88 of pre-hepatic pulsatile insulin. With those values from literature and the extrapolation
89 limit point (0,0), we obtained the following relationships

$$B_{\text{hep,ins}} = 0.000993I_{\text{plas}}^2 + 0.591I_{\text{plas}}$$

$$A_{\text{hep,ins}} = 0.003068I_{\text{plas}}^2 + 2.995I_{\text{plas}}$$

90

$$I_{\text{hep,pul}} = B_{\text{hep,ins}} + A_{\text{hep,ins}} \left| \sin\left(\frac{\pi}{P}t\right) \right|$$

$$I_{\text{hep,npul}} = B_{\text{hep,ins}} + \frac{2}{\pi} A_{\text{hep,ins}}$$

91

92 where I_{plas} denotes plasma insulin level, $B_{\text{hep,ins}}$ denotes basal level of pre-hepatic pulsatile
93 insulin, $A_{\text{hep,ins}}$ denotes the amplitude of pre-hepatic pulsatile insulin, $I_{\text{hep,pul}}$ denotes
94 pre-hepatic pulsatile insulin, P denotes the period of the pulses, $I_{\text{hep,npul}}$ denotes
95 pre-hepatic non-pulsatile insulin, which was used in the simulation of the feeding
96 experiment. With above formulas, the fraction of pulsatile pre-hepatic insulin is in the
97 range 60%-70%, which is consistent with reported values in the literature. Plasma insulin
98 level was taken from ⁷ to build the insulin input for the refeeding experiment while

99 insulin levels for the infusion experiments was assumed to be the insulin level 1 hour
100 after the beginning of feeding in the refeeding experiment.

101 **Simulation**

102 We fitted the model to the two data sets simultaneously. Specifically, in numerical
103 optimization, we tried to minimize the root mean square (RMS) difference between
104 model simulation (y) and the measured data points (\hat{y}),

$$105 \quad RMS = \sqrt{\sum_{j=1}^{n_r} \frac{(y_{rj} - \hat{y}_{rj})^2}{\sigma_{rj}^2} + \sum_{i=1}^{n_i} \frac{(y_{ij} - \hat{y}_{ij})^2}{\sigma_{ij}^2}}$$

106 where suffix r and i denote refeeding and infusion experiments respectively, σ denotes
107 the standard deviation of the measured data point, and n denotes the number of data
108 points.

109

110 All the simulation work was done based on the SBPD toolbox for Matlab. The SBPD
111 toolbox was modified in parts for our special purpose. A differential evolution based
112 global optimizer was employed to fit the parameters in the model. We allowed a large
113 parameter space for the fitting procedure to search. Each optimization task was repeated
114 50 times. The optimizer returns a population of parameters that give rise to acceptable
115 fitting results. We took not only the best fitting result for further analyses, but also those
116 fitting results that are acceptable based on the Akaike information criterion with
117 correction (AICc), with a relative likelihood of more than 0.37 (corresponding to 2 units
118 difference in AICc). The definition of AICc reads

$$119 \quad AICc = 2P + RMS^2 + N \log(2\pi) + 2 \frac{P(P+1)}{N-P-1}$$

120 where P is the number of fitted parameters, N is the number of data points.

121

122 We further made sure that the fitting results for analysis were well separated in terms of
123 Euclidean distance, by filtering out inferior solutions (in terms of RMS) residing in the
124 vicinity, defined by the relative distance filter (rDF) $d_r < 0.1$, of a superior one. In
125 particular, the relative distance d_r between two parameter vectors is defined as

126
$$d_r = \sqrt{\frac{1}{P} \sum_{k=1}^P \frac{(v_{i,k} - v_{j,k})^2}{v_{j,k}^2}}$$

127 where suffix i and j are index for parameter vectors with \mathbf{V}_i being inferior in terms of
128 RMS, k is the index for dimension within parameter vector, P is the number of dimension
129 of parameter vectors (i.e. number of fitted parameters).

130

131 We also investigated the response of the fitted model to variations in insulin levels and
132 quantified the robustness to variations in insulin levels by the mean of AICc (mAICc),
133 which is computed based on model responses to different insulin doses. The responses of
134 the fitted model to 31 different insulin levels, linearly sampled in the range from 85% to
135 115%, were used to calculate mAICc. Models, as well as fitting results, were finally
136 ranked by mAICc. A relative likelihood of more than 0.37 (corresponding to 2 units
137 difference in mAICc) is used in gating.

138 **Parameter identifiability analysis**

139 We performed parameter identifiability analysis based on the minimal model.
140 Considering that measurements of IRS1/2 and Akt were present in the data sets used for
141 fitting while no measurement of insulin receptor or aPKC is available, we carried out the

142 identifiability analysis for parameters directly involved in insulin receptor and aPKC. In
143 particular, the parameter boundary [0.01 100], which was used in the previous fittings for
144 determining the minimal model, was divided to four bins: [0.01 0.1], [0.1 1], [1 10] and
145 [10 100] in order to generate diverse solutions. The model was fitted with one particular
146 parameter being confined to one of the four bins while boundaries for other parameters
147 were as before. Each fitting was repeated five times. This was done for eight parameters:
148 r_{1f} , r_{1b} , r_{2f} , r_{3f} , r_{4f} , d_{0f} , d_{0b} and d_{2f} . For d_{1f} which represents the rate of the conformational
149 change of the partially activated aPKC molecule, the boundary [50 500] was divided into
150 2 bins: [50 100] and [100 500] and corresponding optimization tasks were performed.
151 Altogether, the identifiability analysis consists of 170 optimization tasks ($8 \times 4 \times 5 + 2 \times 5$),
152 the results of which were further analyzed in the following steps.

153 At first, we checked insulin receptor dynamics. Previous *in vitro* experimental studies
154 using metabolic active rat hepatocytes indicated that insulin receptor internalization and
155 recycling can quickly follow physiological levels of insulin pulses¹⁴. However, we have
156 found that some of the fitted results were associated with slow receptor internalization
157 and recycling such that insulin receptors cannot follow 5-min pulses of insulin (see an
158 example in Supplementary Figure 7). These fitting results were excluded from further
159 analysis.

160 Secondly, we applied the AICc criteria, which resulted in 4396 acceptable parameter sets.
161 Thirdly, we applied the relative distance filter, which reduce the number of parameter
162 sets to 528. And finally, we applied the mAICc criteria, which resulted in 13 parameter
163 sets. The distribution of each parameter after each step was presented in Supplementary
164 Figure 2 (b) and (c).

165 In principle, the genetic algorithm we used converges to the global minimum when
166 running time approaches infinity ¹⁵. However in practice, the algorithm has to be
167 terminated by empirical rules. Consequently, the global minimum was likely not
168 identified in our numerical studies.

169 The identifiability analysis showed that 14 parameters were well confined in relative
170 small ranges (both the ratio between the maximum and the median, and the ratio between
171 the median and the minimum were smaller than two, see Supplementary Figure 1). The
172 other 11 parameters were not well confined (at least one of the ratios was larger than two,
173 see Supplementary Figure 1).

174 **Fitted Parameter values**

175 Fitted Parameter values are provided in Supplementary Data 1, including the 13
176 parameter sets, as gated by mAICc, for M4 in the identifiability analysis.

177 **Matlab codes for generating main figures**


178 Matlab codes for generating main figures in both the main text and the Supplementary
179 Information are provided in Supplementary Software 1.

180

181 **Supplementary Figures**

182 **Supplementary Figure 1. Distribution of fitted parameters in the**
 183 **minimal model**


184 Supplementary Figure 1 (a)



185

186


187 Supplementary Figure 1 (b)



188

189


190 Supplementary Figure 1 (c)



191


192 Supplementary Figure 1 (a) Box and whisker plot for fitted parameters from the
 193 identifiability analysis. Each parameter is normalized such that the median value is 1
 194 (red). The upper and lower quartiles (p_{75} and p_{25}) are marked by green. The range, from
 195 $p_{25}-1.5(p_{75}-p_{25})$ to $p_{75}+1.5(p_{75}-p_{25})$, is marked by blue. Mean \pm standard deviation for each
 196 parameter are shown along the labels of the vertical axis. The x-axis is truncated at 20 to
 197 show more detail in the small range. The maximum of parameter r_{1b} reaches 400. (b) and
 198 (c), distribution of parameters resulting from AICc, relative distance filter (rDF), and
 199 mAICc criterion in the identifiability analysis. Mean and median values are marked by
 200 red cross and green square respectively. (b) shows kinetic parameters, (c) shows
 201 parameters in various Hill functions.

202 **Supplementary Figure 2. Multiple fitting results (related to Fig. 2 in the**
 203 **main text)**



204
 205 Supplementary Figure 2 Multiple fitting results, coded by color, of the minimal model.
 206 The associated 13 parameter sets are included in the xls file in the supplement.
 207 Experimental data are indicated by black circles with error bars (s.e.m). The main
 208 difference is the timing of the aPKC switch.
 209

210 **Supplementary Figure 3 Multiple fitting results of M3**



211


212 Supplementary Figure 3, Two fitting result (green and blue), gated by mAICc, of M3.

213

214 **Supplementary Figure 4. Model response to different insulin doses is**

215 **robust (related to Fig. 4 in the main text)**


216 Supplementary Figure 4 (a)



217

218


219 Supplementary Figure 4 (b)



220

221

222 Supplementary Figure 4 (c)



223

224 Supplementary Figure 4. Response of the minimal model, based on the 13 parameter sets

225 resulting from the identifiability analysis, to different insulin doses are shown (a). The


226 time of aPKC switch-off (b) and the level of Akt rebound (c) are also shown.

227

228 **Supplementary Figure 5. Response to insulin profiles with different**
229 **dynamic features (related to Fig. 5 in the main text)**


230

231 Supplementary Figure 5 (a)




232
233

234 Supplementary Figure 5 (b)



235
236




238
 239 Supplementary Figure 5, The response of the minimal model to insulin profiles with
 240 different dynamical features. The time of aPKC switch-off (a), the level of Akt rebound
 241 (b) and the AUC of aPKC in first and second hour (c) are shown.
 242

243 **Supplementary Figure 6. Response to different pulsatile insulin**

244 **(related to Fig. 6 in the main text)**


245 Supplementary Figure 6 (a)



246

247

248 Supplementary Figure 6 (b)



249

250 Supplementary Figure 6 (a), Area under curve, corresponding to Fig. 6 in the main text, is

251 compared for high and low amplitude of insulin pulses. The trend here is similar to


252 Fig.5F in the main text. (b) Response of the model to pulsatile insulin with high and low

253 amplitude. Multiple simulation results, coded by color, are shown. The associated 13

254 parameter sets are included in the xls file in the supplement.

255

256 **Supplementary Figure 7 Two patterns of insulin receptor dynamics**



257
 258 Supplementary Figure 7 Example of the two patterns of insulin receptor dynamics in the
 259 simulation of infusion experiments. Although the two curves of insulin receptor (bottom
 260 row) are similar in the refeeding experiment (rightmost column), they are different in the
 261 infusion experiments. Insulin receptor can either follow insulin pulses (green curves,
 262 consistent with published experiments) or not (blue curves, contrary to published
 263 experiments). Parameter sets associated with the fast pattern of insulin dynamics were
 264 further analyzed.
 265

266 **Supplementary References**

- 267 1. Schmidt, H. SBaddon: high performance simulation for the Systems Biology Toolbox
268 for MATLAB. *Bioinformatics* **23**, 646–647 (2007).
- 269 2. Dhooge, A., Govaerts, W. & Kuznetsov, Y. A. MATCONT: A MATLAB package
270 for numerical bifurcation analysis of ODEs. *ACM Trans. Math. Softw.* **29**, 141–164
271 (2003).
- 272 3. Ravichandran, L. V., Chen, H., Li, Y. & Quon, M. J. Phosphorylation of PTP1B at
273 Ser50 by Akt impairs its ability to dephosphorylate the insulin receptor. *Mol.*
274 *Endocrinol.* **15**, 1768–1780 (2001).
- 275 4. Luo, M. *et al.* Phosphorylation of Human Insulin Receptor Substrate-1 at Serine 629
276 Plays a Positive Role in Insulin Signaling. *Endocrinology* **148**, 4895–4905 (2007).
- 277 5. Ozcan, L. *et al.* Activation of Calcium/Calmodulin-Dependent Protein Kinase II in
278 Obesity Mediates Suppression of Hepatic Insulin Signaling. *Cell Metab.* **18**, 803–815
279 (2013).
- 280 6. Guglielmo, G. M. D., Baass, P. C., Authier, F., Posner, B. I. & Bergeron, J. J. M.
281 Insulin receptor internalization and signalling. *Mol. Cell. Biochem.* **182**, 59–63
282 (1998).
- 283 7. Kubota, N. *et al.* Dynamic Functional Relay between Insulin Receptor Substrate 1
284 and 2 in Hepatic Insulin Signaling during Fasting and Feeding. *Cell Metab.* **8**, 49–64
285 (2008).
- 286 8. Taniguchi, C. M., Emanuelli, B. & Kahn, C. R. Critical nodes in signalling pathways:
287 insights into insulin action. *Nat Rev Mol Cell Biol* **7**, 85–96 (2006).

- 288 9. Farese, R. V., Sajan, M. P. & Standaert, M. L. Insulin-Sensitive Protein Kinases
289 (Atypical Protein Kinase C and Protein Kinase B/Akt): Actions and Defects in
290 Obesity and Type II Diabetes. *Exp. Biol. Med.* **230**, 593–605 (2005).
- 291 10. Farese, R. V. & Sajan, M. P. Metabolic functions of atypical protein kinase C: “good”
292 and “bad” as defined by nutritional status. *Am. J. Physiol. - Endocrinol. Metab.* **298**,
293 E385–E394 (2010).
- 294 11. Standaert, M. L., Bandyopadhyay, G., Kanoh, Y., Sajan, M. P. & Farese, R. V.
295 Insulin and PIP3 Activate PKC- ζ by Mechanisms That Are Both Dependent and
296 Independent of Phosphorylation of Activation Loop (T410) and Autophosphorylation
297 (T560) Sites†. *Biochemistry (Mosc.)* **40**, 249–255 (2001).
- 298 12. Matveyenko, A. V., Veldhuis, J. D. & Butler, P. C. Measurement of pulsatile insulin
299 secretion in the rat: direct sampling from the hepatic portal vein. *Am. J. Physiol. -*
300 *Endocrinol. Metab.* **295**, E569–E574 (2008).
- 301 13. Matveyenko, A. V., Veldhuis, J. D. & Butler, P. C. Adaptations in pulsatile insulin
302 secretion, hepatic insulin clearance, and β -cell mass to age-related insulin resistance
303 in rats. *Am. J. Physiol. - Endocrinol. Metab.* **295**, E832–E841 (2008).
- 304 14. Goodner, C. J., Sweet, I. R. & Harrison, H. C. Rapid Reduction and Return of
305 Surface Insulin Receptors After Exposure to Brief Pulses of Insulin in Perifused Rat
306 Hepatocytes. *Diabetes* **37**, 1316–1323 (1988).
- 307 15. Ghosh, S., Das, S., Vasilakos, A. V. & Suresh, K. On Convergence of Differential
308 Evolution Over a Class of Continuous Functions With Unique Global Optimum.
309 *IEEE Trans. Syst. Man Cybern. Part B Cybern.* **42**, 107–124 (2012).
- 310